SPC Lifesciences files draft papers with SEBI for IPO

Pharmaceutical ingredients maker SPC Lifesciences Ltd has filed preliminary papers with the capital market regulator SEBI to raise funds through an initial public offering. The Initial Public Offering (IPO) consists of fresh issuance of equity shares worth Rs 300 crore and an Offer For Sale (OFS) of 89.39 lakh equity shares by promoter - Snehal Rajivbhai Patel - according to the draft red herring prospectus.

The company may consider a pre-IPO placement aggregating up to Rs 60 crore and if such a placement is completed, then the fresh issue size will be reduced.

The proceeds from the fresh issue will be used to pay a debt, support working capital needs and fund capital expenditure requirements for setting up Phase-2 at its Dahej facility in order to expand product offerings of pharmaceutical intermediates, and for general corporate purposes.

Gujarat-based SPC Lifesciences is a leading manufacturer of advanced intermediates for certain key active pharmaceutical ingredients.

The advanced pharmaceutical intermediates which are manufactured by the company are used in growing therapeutic areas, including cardiovascular, vasodilator (anti-platelet), anti-psychotic and anti-depressants.

Ambit and HDFC Bank are the book-running lead managers to manage the company's initial share sale. The shares of the company will be listed on the BSE and NSE.

SEE ALSO:
SEBI bans 6 entities from securities market in front running case; impounds ₹2.23 crore
Sensex rallies 346 pts, Nifty near 17,100 on firm global markets